131 related articles for article (PubMed ID: 38312022)
1. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
[TBL] [Abstract][Full Text] [Related]
2. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
4. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
[TBL] [Abstract][Full Text] [Related]
5. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
[TBL] [Abstract][Full Text] [Related]
6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
7. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
[TBL] [Abstract][Full Text] [Related]
8. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
9. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
10. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
11. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
12. Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.
Solomon SR; Aubrey MT; Zhang X; Jackson KC; Roark CL; Freed BM; Morris LE; Holland HK; Solh MM; Bashey A
Transplant Cell Ther; 2022 Sep; 28(9):601.e1-601.e8. PubMed ID: 35788088
[TBL] [Abstract][Full Text] [Related]
13. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia.
Arima N; Kanda J; Tanaka J; Yabe T; Morishima Y; Kim SW; Najima Y; Ozawa Y; Eto T; Kanamori H; Mori T; Kobayashi N; Kondo T; Nakamae H; Uchida N; Inoue M; Fukuda T; Ichinohe T; Atsuta Y; Kanda Y
Biol Blood Marrow Transplant; 2018 Apr; 24(4):717-725. PubMed ID: 29197675
[TBL] [Abstract][Full Text] [Related]
14. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
15. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
16. Role of donor HLA class I mismatch, KIR-ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation.
Graczyk-Pol E; Rogatko-Koros M; Nestorowicz K; Gwozdowicz S; Mika-Witkowska R; Pawliczak D; Zubala M; Szlendak U; Witkowska A; Tomaszewska A; Nasilowska-Adamska B; Szczepinski A; Wojcik M; Halaburda K; Nowak J
HLA; 2018 Dec; 92 Suppl 2():42-46. PubMed ID: 30168290
[TBL] [Abstract][Full Text] [Related]
17. Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation.
Zhao Y; Gao F; Wu Y; Shi J; Luo Y; Tan Y; Yu J; Lai X; Zhang M; Zhang W; Huang H
Front Immunol; 2020; 11():614488. PubMed ID: 33633734
[TBL] [Abstract][Full Text] [Related]
18. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
[TBL] [Abstract][Full Text] [Related]
19. [Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].
Bao XJ; He J; Chen ZX; Wu DP; Yao L; Yuan XN; Cen JN; Qiu QC; Di WY; Zhang H; Zhang J; Zhou XH; Xu HX
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):510-3. PubMed ID: 18078124
[TBL] [Abstract][Full Text] [Related]
20. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
